Researchers created a new tool that can measure patient satisfaction with comprehensive pharmacy programs.
Measuring the quality and sustainability of comprehensive medication management (CMM) services is important, and patient satisfaction is a key component for measuring the quality of CMM services; however, pharmacy as a profession has been impeded by a lack of reliable tools to assess patient satisfaction with the quality of CMM services.
Jean Moon, PharmD, BCACP, of the University of Minnesota College of Pharmacy, and colleagues developed a psychometrically valid questionnaire for measuring patient satisfaction with CMM services, and they described this tool and its validity and reliability in a study published in the January 2016 issue of the Journal of Managed Care & Specialty Pharmacy.
“Without appropriate patient satisfaction measures demonstrating value, pharmacists can be at a disadvantage when requesting reimbursement for these clinical services,” the authors wrote.
CMM programs are designed to ensure that each patient’s medications are individually assessed so that each medication is appropriate for the patient, effective for the medical condition, safe given the comorbidities and other medications being taken, and able to be taken by the patient as intended. CMM also includes an individualized care plan outlining the intended goals of therapy and the appropriate follow-up to determine actual patient outcomes.
Dr Moon and co-workers developed the survey tool with collaborative input from administrators, practitioners, patients, students, pharmacists, university faculty, and a health literacy committee and a multiphase development process. Validation studies were conducted across 2 urban ambulatory care health system settings providing CMM services. The survey consisted of 10 items related to 3 domains: medication-related needs, pharmacist-patient engagement, and overall satisfaction. The surveys were mailed, collected, and analyzed for descriptive statistics, internal consistency, and factorial composition.
A total of 195 surveys were returned for analysis (survey response rate, 19.2%). The survey items were found to have high internal consistency and were considered highly reliable in the 2 different health systems addressed. The instrument was relatively simple to administer, the researchers stated, and they recommended additional analysis to evaluate the survey instrument as a measure of quality assurance across additional programs.
“Patient satisfaction is an integral part of measuring a quality service, and this tool may serve other programs following the industry standard CMM model with a reliable mechanism to assess and compare performance,” the authors concluded.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More